Revance Aesthetics Portfolio TEOXANE Dermal Fillers 2020

Revance Therapeutics announced an exclusive U.S. distribution agreement for TEOXANE's FDA-approved RHA dermal fillers, positioning the company as a premium leader in facial injectables. The agreement provides access to the $1.1B U.S. filler market with innovative, differentiated products for correcting dynamic facial wrinkles and folds.